Abstract
Objectives
To evaluate the efficacy of tamsulosin therapy in reducing ureteral double-J stent morbidity by evaluating USSQ, IPSS, QOL and VAS (primary objective) and to evaluate the morbidity and or complication(s) associated with indwelling double-J ureteral stent(s) and to evaluate the safety of tamsulosin therapy for “morbidity associated with double-J stents” by evaluating its tolerability, side effects and adverse events if any (secondary objective) as per protocol.
Methods
After institutional review board approval, 60 consecutive patients with a double-J ureteral stent inserted after percutaneous nephrolithotomy or ureteroscopic stone treatment were randomly assigned to receive tamsulosin 0.4 mg, or a placebo for 4 weeks. The validated USSQ, VAS and IPSS were completed before stent insertion, at 3 days and 4 weeks after stent insertion and at 2 weeks after stent removal. Data were statistically analyzed for efficacy and tolerability of one drug over the other using Wilcoxon signed-rank test, Mann–Whitney test and Student’s t test.
Results
Patients receiving tamsulosin compared with the placebo showed significant decrease in urinary index score, pain index score, work performance score, VAS score at loin area, VAS score at flank, VAS score at suprapubic area, average VAS score, need for antibiotics, number of hospital visits (P < 0.05) at the end of fourth weeks. Decrease in values were also observed in IPSS score, general health score, quality of sex score and IPSS-quality of life (QOL) score in patients taking tamsulosin but, however, the decrease was not significant. No patients discontinued medication because of side effects.
Conclusion
We conclude that ureteral stenting using double-J stents with concomitant tamsulosin therapy was generally well tolerated, safe, effective and significantly beneficial in reducing stent morbidity in the majority of our patients. We advocate the routine use of concomitant tamsulosin therapy in eligible patients undergoing ureteral stenting in order to minimize stent morbidity.
Similar content being viewed by others
References
Gerber GS, Lyon ES (1993) Endourological management of upper tract urothelial tumors. J Urol 150:2
Leventhal EK, Rozanski TA, Crain TW, Deshon GE (1995) Indwelling ureteral stents as definitive therapy for distal ureteral calculi. J Urol 153:34–36
Joshi HB, Okeke A, Newns N, Keely FX, Timoney AG (2002) Characterization of urinary symptoms in patients with ureteral stents. Urology 59(4):511–516
Singh I, Gupta NP, Hemal AK, Aron M, Seth A, Dogra PN (2001) Severely encrusted polyurethane ureteral stents: management and analysis of potential risk factors. Urology 58(4):526–531
Menon AN, Talpur AA, Menon JM (2007) Indication and complications of indwelling ureteral stenting at NMCH. Nawabshah. Pak J Surg 3:187–191
Singh I (2003) Indwelling ureteral JJ stent: a current perspective and review of literature. Ind J Surg 65:405–412
Joshi HB, Stainthorpe A, Macdonagh RP et al (2003) Indwelling ureteral stents: evaluation of symptoms, quality of life and utility. J Urol 169:1065–1069
Deliveliotis C, Chrisofos M, Gougousis E et al (2006) Is there a role for alpha-1 blockers in treating double-j stent-related symptoms? Urology 67:35–39
Damiano R, Autorino R, De Sio M et al (2008) Effect of tamsulosin in preventing ureteral stent related morbidity: a prospective study. J Endourol 22:651–656
Beddingfield R, Pedro RN, Hinck B et al (2009) Alfuzosin to relieve ureteral stent discomfort: a prospective, randomized, placebo controlled study. J Urol 181:170–176
Nazim SM, Ather MH (2012) Alpha-blockers impact stent- related symptoms : a randomized, double-blind, placebo-controlled trial. J Endourol 26(9):1237–1241
Wang CJ, Huang SW, Chang CH (2009) effects of tamsulosin on lower urinary tract symptoms due to double-J stent: a prospective study. Urol Int 83:66–69
Wang CJ, Huang SW, Chang CH (2009) Effects of specific alpha-1A/1D blocker on lower urinary tract symptoms due to double-J stent: a prospectively randomized study. Urol Res 37(3):147–152
Lamb AD, Vowler SL, Johnston R et al (2011) Meta-analysis showing the beneficial effect of alpha blockers on ureteric stent discomfort. BJU Int 108:1894–1902
Yakoubi R, Lemdani M, Monga M et al (2011) Is there a role for α-blockers in ureteral stent related symptoms? A systematic review and meta-analysis. J Urol 186(3):928–934
Dellis AE, Keeley FX Jr, Manolas V, Skolarikos AA (2014) Role of α-blockers in the treatment of stent-related symptoms: a prospective randomized control study. Urology. 83(1):56–61
Conflict of interest
The authors declare that “we have no conflict of interest” in the publication of the above manuscript.
Author information
Authors and Affiliations
Corresponding author
Additional information
Dr. Iqbal Singh is formerly a Fellow, Department of Urology (Robotics & Min Inv Urology), WFUMS, NC, USA.
Rights and permissions
About this article
Cite this article
Singh, I., Tripathy, S. & Agrawal, V. Efficacy of tamsulosin hydrochloride in relieving “double-J ureteral stent-related morbidity”: a randomized placebo controlled clinical study. Int Urol Nephrol 46, 2279–2283 (2014). https://doi.org/10.1007/s11255-014-0825-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-014-0825-8